Biologic Choice May Affect Steroid Taper in RA

Adults with rheumatoid arthritis starting certain biologics had lower odds of stopping steroids than those starting JAK inhibitors.

Updated on Nov. 2, 2026 in Arthritis

Isometric editorial illustration of amber tablets stepping down in height beside a sealed glass vial on a pale surface.
A retrospective Hong Kong registry study found adults with rheumatoid arthritis starting certain biologics were less likely to stop steroids than those starting JAK inhibitors. AI Illustration. Upload story photo >

A retrospective Hong Kong registry study found that adults with rheumatoid arthritis who started certain biologic drugs were less likely to stop taking glucocorticoids (steroids) than those who started JAK inhibitors. The study was published online September 23, 2026, in Seminars in Arthritis and Rheumatism, and its findings may interest patients and clinicians managing RA with steroid tapers.

Why it matters

Glucocorticoids are effective for quick symptom control in rheumatoid arthritis but carry long-term risks, so reducing reliance on them is a central treatment goal. The findings suggest the choice of advanced therapy may influence how soon patients can taper off steroids, a question that has received less attention than drug efficacy alone.

This retrospective observational study drew on a population-based registry and included 1,421 adults with rheumatoid arthritis who began a biologic or targeted synthetic DMARD while taking glucocorticoids, with a median age of 57 and 81.8% women. Researchers adjusted for relevant confounders, but because the design is observational, the reported odds differences describe association rather than proven drug effects.

The players

Seminars in Arthritis and Rheumatism

A peer-reviewed rheumatology journal that publishes clinical and translational research on arthritis and related musculoskeletal conditions.

The details

Glucocorticoids reduce inflammation quickly but are usually tapered over time because of side effects with prolonged use. Biologic agents such as anti-TNF drugs, anti-CD20 agents and CTLA4-Ig, and JAK inhibitors, a targeted synthetic class, work on different parts of the immune response. The registry analysis compared how often patients stopped steroids after starting each class, tracking discontinuation at 3 and 6 months.

Timeline

  1. January 2006 to December 2021: Period when patients began their first-ever biologic or targeted synthetic DMARD in the Hong Kong registry.

  2. September 23, 2026: Study published online in Seminars in Arthritis and Rheumatism.

Health Landscape

Current RA management aims to bring patients into remission while limiting steroid exposure, and newer biologic and targeted therapies have expanded treatment options over the past two decades. This registry comparison adds real-world evidence from an Asian population to a growing body of data on how advanced therapies affect steroid use.

If you have rheumatoid arthritis and are on glucocorticoids, this study is worth raising with your rheumatologist when discussing long-term steroid plans. Any question about changing or starting a biologic or JAK inhibitor belongs in a conversation with your physician, not a decision based on this study alone.

The takeaway

Steroid reduction is a key goal in rheumatoid arthritis, and drug choice may matter for it. Patients and clinicians can ask about steroid taper goals as part of ongoing RA treatment planning.

Further reading

For more on the conditions and treatments behind these findings, explore our Arthritis coverage.

Source note: This article includes information reported by Medscape.